$NVNO

enVVeno Medical (NVNO) has received FDA Investigational Device Exemption (IDE) approval for its pivotal TAVVE trial, which will evaluate the enVVe venous valve for severe deep Chronic Venous Insufficiency (CVI). This approval paves the way for a first-in-class non-surgical solution for approximately 3 million U.S. patients, a condition with limited viable therapies. The company also reported having $25 million in cash and investments, expected to fund operations until Q3 2027, allowing them to execute the trial and strengthen their market position.